AR044476A1 - Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades - Google Patents

Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades

Info

Publication number
AR044476A1
AR044476A1 ARP040101905A ARP040101905A AR044476A1 AR 044476 A1 AR044476 A1 AR 044476A1 AR P040101905 A ARP040101905 A AR P040101905A AR P040101905 A ARP040101905 A AR P040101905A AR 044476 A1 AR044476 A1 AR 044476A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
diseases
independently selected
nhc
Prior art date
Application number
ARP040101905A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312840A external-priority patent/GB0312840D0/en
Priority claimed from GB0312842A external-priority patent/GB0312842D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR044476A1 publication Critical patent/AR044476A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos, procedimientos para la preparación, intermedios usados en la preparación, composiciones que los contienen y usos. Los compuestos son útiles en numerosas enfermedades, trastornos y afecciones, en particular en enfermedades, trastornos y afecciones inflamatorios, alérgicos y respiratorios. Reivindicación 1: Un compuesto de fórmula (1) en la que el grupo CH2-C(=O)NH-bencil-Q1-Q2-Q3-Q4 está en la posición meta o para, y R1 y R2 se seleccionan independientemente entre H y alquilo C1- 4; Q1 es (CH2)n donde n es un número entero seleccionado entre 0 y 1; Q2 es un grupo seleccionado entre NH, -C(=O)NH-, -NHC(=O)-, -NH-C(O)-NH y -SO2NH; Q3 es un enlace sencillo, un alquileno C1-4 sustituido opcionalmente con OH o un grupo (CH2)m-O- (CH2)p donde m y p son números enteros seleccionados independientemente entre 1, 2 ó 3; Q4 se selecciona entre el grupo de fórmulas (2) en la que * representa el punto de unión a Q3 y R3, R4, R5, R6 y R7 se seleccionan independientemente entre H, fenoxi, alquilo C1-4, OR9, SR9, halo, CF3, OCF3, COOR9, SO2NR8R9, CONR8R9, NHR8R9, NHCOR9, CH2-NHC(=O)NH-; R9 con la condición de que al menos 2 de R3 a R7 sean igual a H; en la que R8 se selecciona entre H o alquilo C1-4 y R9 se selecciona entre H, alquilo C1-4, bencilo opcionalmente sustituido con 1, 2, 3 ó 4 alcoxi C1-4 y un grupo de fórmula (3) en la que q es un número entero seleccionado entre 0, 1, 2 y 3; o, si es apropiado, sus sales y/o isómeros, tautómeros, solvatos o variaciones isotópicas farmacéuticamente aceptables de los mismos.
ARP040101905A 2003-06-04 2004-06-03 Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades AR044476A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0312840A GB0312840D0 (en) 2003-06-04 2003-06-04 2-amino-pyridine derivatives useful for the treatment of diseases
GB0312842A GB0312842D0 (en) 2003-06-04 2003-06-04 2-amino-pyridine derivatives useful for the treatment of diseases

Publications (1)

Publication Number Publication Date
AR044476A1 true AR044476A1 (es) 2005-09-14

Family

ID=33512686

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101905A AR044476A1 (es) 2003-06-04 2004-06-03 Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades

Country Status (14)

Country Link
EP (1) EP1633714B1 (es)
JP (1) JP2006526604A (es)
AR (1) AR044476A1 (es)
AT (1) ATE384697T1 (es)
BR (1) BRPI0410660A (es)
CA (1) CA2527334A1 (es)
DE (1) DE602004011513T2 (es)
ES (1) ES2298757T3 (es)
MX (1) MXPA05013059A (es)
NL (1) NL1026327C2 (es)
PA (1) PA8604201A1 (es)
TW (1) TW200505862A (es)
UY (1) UY28343A1 (es)
WO (1) WO2004108675A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PL2322525T3 (pl) 2006-04-21 2014-03-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
FR2953720B1 (fr) * 2009-12-11 2012-05-11 Oreal Utilisation de derives de benzyloxy-ethylamines comme conservateur,
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
SG10202110259QA (en) 2017-10-05 2021-10-28 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN114853728B (zh) * 2022-05-07 2023-11-07 四川制药制剂有限公司 一种富马酸伏诺拉生片及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541197A (en) * 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
GB2305665A (en) * 1995-09-26 1997-04-16 Merck & Co Inc Selective ß3 agonists for the treatment of diabetes aand obesity
CA2458534C (en) * 2001-09-14 2011-11-01 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases

Also Published As

Publication number Publication date
EP1633714B1 (en) 2008-01-23
CA2527334A1 (en) 2004-12-16
TW200505862A (en) 2005-02-16
EP1633714A1 (en) 2006-03-15
UY28343A1 (es) 2005-01-31
ES2298757T3 (es) 2008-05-16
WO2004108675A1 (en) 2004-12-16
NL1026327A1 (nl) 2004-12-07
BRPI0410660A (pt) 2006-06-20
ATE384697T1 (de) 2008-02-15
DE602004011513D1 (de) 2008-03-13
DE602004011513T2 (de) 2009-01-29
PA8604201A1 (es) 2004-12-16
NL1026327C2 (nl) 2005-05-26
JP2006526604A (ja) 2006-11-24
MXPA05013059A (es) 2006-03-02

Similar Documents

Publication Publication Date Title
AR044476A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
AR044475A1 (es) Derivados de 2-amino -piridina utiles para el tratamiento de enfermedades
AR047509A1 (es) Derivados de sulfonamida como antagonistas de receptores adrenergicos beta2
AR048322A1 (es) Compuestos para el tratamiento de afecciones inflamatorias, alergicas y respiratorias
CO5700776A2 (es) Compuestos utiles para el tratamiento de enfermedades
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
YU96103A (sh) Novi derivati indola sa afinitetom za 5-ht6 receptor
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
CR10145A (es) Derivados de tropano útiles en terapia (divisional exp. 6800)
AR021354A1 (es) Procedimiento para la preparacion de un compuesto derivado de quinolina y un procedimiento para preparar una composicion farmaceutica
HRP20070452T3 (en) Sulfonamide derivatives for the treatment of diseases
AR048377A1 (es) Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
PA8586401A1 (es) 4-piperazinilbencenosulfonilindoles y uso de los mismos
PE20050013A1 (es) Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
RS51888B (en) N- (PHENYL (PIPERIDIN-2-IL) METHYL) BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
AR031867A1 (es) Compuestos derivados de fenoxibencilamina como ssri, su uso en la preparacion de medicamentos, procedimiento de preparacion del compuesto e intermediarios utiles
AR049512A1 (es) Derivados de tetrahidrofurano tetraciclicos. composiciones farmaceuticas
DE60322200D1 (de) Formoterol und ciclesonid aerosol-formulierungen
DK0669919T3 (da) Anvendelse af dimethylbenzofuraner og dimethylbenzopyraner som 5-HT3-antagonister
AR045090A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4
TNSN04106A1 (en) Triazolo-quinolin derivatives useful as adenosine receptor ligands

Legal Events

Date Code Title Description
FB Suspension of granting procedure